Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aptorum Group Limited (APM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6600-0.0700 (-4.05%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7300
Open1.7600
Bid1.6000 x 1300
Ask1.7000 x 800
Day's Range1.5701 - 1.8000
52 Week Range1.5700 - 4.9400
Volume168,752
Avg. Volume134,469
Market Cap59.099M
Beta (5Y Monthly)-0.22
PE Ratio (TTM)8.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

    The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is a bioavailability/food effect study that will take four months to complete. The bioavailability/food effect study aims to compare the relative bioavailability of the newly developed SACT-1 pediatric formulation in healthy adult subjects. The above study will follow a planned Phase 1b/2a trial in pediatric patients with relapsed or refracto

  • Simply Wall St.

    What Kind Of Shareholders Hold The Majority In Aptorum Group Limited's (NASDAQ:APM) Shares?

    Every investor in Aptorum Group Limited ( NASDAQ:APM ) should be aware of the most powerful shareholder groups...

  • Benzinga

    Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

    Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed. No subjects were dropped out of the studies, and no serious adverse events were observed. Additionally, no clinically relevant changes regarding vital signs, electrocar

Advertisement
Advertisement